After a record year in 2024, where companies raised ₹1.36 lakh crore through the QIP route, the figure has seen a dip this ...

But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study. And through the first nine months of 2025, Zepbound generated $9.3 billion ...

Biohaven shares fell 16.19% in after-hours trading Wednesday after its Phase 2 depression drug trial missed the primary ...

Retirement accounts clawed back much of what was lost while highlighting how deeply policy shifts can hit workers’ savings.

How a reclusive former auditor turned $5,000 into $22 million without using options, "moonshot" investments, or leverage of any kind.

Agios upgraded after FDA approval of Aqvesme for thalassemia. Explore AGIO’s financial outlook, upside potential, and future ...

We do not have to be losing 350,000 people globally to cervical cancer each year,” said study senior author Abba Gumel.

What is the best time of year to take required minimum distributions from a traditional IRA? A recent study has some ...

William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

On December 12, Wells Fargo analyst Eva Fortea Verdejo indicated her bullish sentiment and assigned a Buy rating to Kiniksa ...

With that background, let’s explore our 15 most promising mid-cap healthcare stocks under $50.

Altimmune has shared an update on the metabolic dysfunction-associated steatohepatitis (MASH) study that sank its stock in June. The 48-week readout linked the top dose of the GLP-1/glucagon dual ...